The meteoric rise of GLP-1 receptor agonists—the blockbuster class of drugs including semaglutide and tirzepatide—has fundamentally altered the landscape of obesity medicine. However, as demand for these medications far outstripped supply, a chaotic, multi-billion-dollar gray market emerged. New data from the U.S. Food and Drug Administration (FDA) reveals a troubling byproduct of this gold rush: more than 1,700 reports of adverse events tied to compounded versions of these drugs, highlighting a systemic failure in patient safety as telehealth entities and compounding pharmacies push the boundaries of regulatory oversight.
The Illusion of Legitimacy: The Case of MEDVi and Beyond
In April 2026, the New York Times spotlighted MEDVi, a gen-AI-driven enterprise that claimed to be the fastest-growing company in history. With reported 2025 sales of $401 million and projected 2026 revenue of $1.8 billion, MEDVi became the face of the "telehealth-compounding" boom. Yet, beneath the veneer of high-tech innovation lay a precarious regulatory reality.
In February 2026, the FDA issued a scathing warning letter to MEDVi, alleging that the company’s branding of compounded semaglutide and tirzepatide misled consumers by obscuring the true source of the drugs and falsely implying equivalence to FDA-approved products like Wegovy and Zepbound. MEDVi responded by claiming the letter was directed at an affiliate, not the company itself. However, historical web archives tell a different story: in early 2026, the site medvi.io served as a funnel, directing customers into an intake system where they were bound by the terms of MEDVi LLC.
This "playbook" is increasingly common. It involves a web of overlapping clinicians, pharmacy networks, and recycled marketing assets. A current investigation into AltRx, another online purveyor of compounded GLP-1s, reveals that the company lists the same physicians—Drs. David Mansour, Ana Lisa Carr, and Kelly Tenbrink—who previously graced the MEDVi website. These same doctors have also appeared on sites for other entities like VitalSlim and Reddi, suggesting a centralized infrastructure providing "clinical" oversight to a fragmented landscape of storefronts.
A Chronology of Regulatory Friction
The current crisis did not emerge in a vacuum; it is the result of a temporary regulatory window that was left wide open for too long.
- March – December 2022: The FDA officially added Wegovy, Ozempic, and tirzepatide to its drug shortage list. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, this designation provided a narrow, legal pathway for pharmacies to produce "essentially copies" of patented drugs.
- September 2025: The scale of the abuse prompted a massive regulatory crackdown, with the FDA issuing more than 55 warning letters to online sellers in a single day.
- May 2025: The final enforcement discretion window for these compounded drugs closed, as the FDA declared the shortages resolved.
- 2026 – Present: The FDA has continued to ramp up pressure, issuing waves of warning letters in February, March, and June 2026. These letters explicitly cite violations of FDCA sections 502(a) and 502(n), focusing on misbranding and the promotion of unapproved products.
Despite these actions, the industry remains defiant. The Outsourcing Facilities Association, representing many of the pharmacies involved, sued the FDA in late 2024, challenging the agency’s authority to declare the shortages "resolved," effectively attempting to keep the lucrative loophole open.
Supporting Data: The Rising Toll on Patient Safety
The sheer volume of adverse event reports is a lagging indicator of a much larger public health crisis. As of May 31, 2026, the FDA had logged 990 reports associated with compounded semaglutide and over 730 related to compounded tirzepatide.
The FDA explicitly warns that these figures are likely significant undercounts. Because many state-licensed compounding pharmacies are not subject to the same stringent federal reporting requirements as traditional drug manufacturers, thousands of incidents likely go unrecorded.
America’s Poison Centers reported a staggering 1,500% increase in GLP-1 agonist exposure cases between 2019 and 2025, totaling 22,966 cases. While many involve accidental therapeutic errors with FDA-approved products, the compounded market presents a unique, heightened risk. Investigators have identified a recurring pattern of 10-fold dosing errors, often linked to confusion over syringe measurement units provided by unregulated kits. These errors, which occur when a patient receives ten times the intended dose, represent a life-threatening risk that does not exist with the pre-filled, measured pens provided by the original manufacturers.
The Economic Engine of the Gray Market
The compounding boom has been immensely profitable. An internal sales dashboard obtained by the Houston Chronicle revealed that Empower Pharmacy, a major player in the space, generated $311 million in the first 10 months of 2024 alone—with 66% of that revenue derived from GLP-1 formulations. This represents a massive leap from the company’s $119 million total revenue in 2022.
Bankers estimate that the compounded weight-loss market has become a $1 billion-per-year industry. This massive influx of capital has fueled aggressive marketing campaigns and the rapid proliferation of "med-spas" and "telehealth clinics," which often operate with minimal clinical vetting.
Implications: Fraud, RICO, and Legislative Reform
The impact of this unregulated market extends beyond medical safety into the realm of financial exploitation. Consumers have reported "traps" in the subscription models of companies like FitRx and Zealthy, where users are hit with hundreds of dollars in unexpected charges, only to find the cancellation process intentionally obstructed. One contributor to WIRED reported an $866 charge after simply attempting to check pricing for compounded tirzepatide.
The RICO Allegations
The connections between infrastructure providers like OpenLoop Health and pharmacies like Triad Rx are now at the center of a pending civil RICO (Racketeer Influenced and Corrupt Organizations Act) complaint. The lawsuit alleges that these entities created a sophisticated network of consumer-facing "storefronts" to sell oral tirzepatide—a drug formulation that pharmaceutical giant Eli Lilly does not produce and for which there is no demonstrated clinical efficacy or systemic absorption. By creating an illusion of a legitimate medical pathway, the complaint argues, these companies engaged in a coordinated scheme to defraud patients.
Legislative Pushback
In Washington, the bipartisan SAFE Drugs Act of 2025 represents the most significant legislative attempt to curb the crisis. The bill seeks to limit the production of "essentially copies" of commercially available drugs to 20 units per month, unless a prescriber certifies a specific, clinically significant difference for a patient.
However, the bill faces intense lobbying. The Alliance for Pharmacy Compounding and the National Community Pharmacists Association are aggressively opposing these limits, arguing that they would restrict patient access to necessary care. Meanwhile, pharmaceutical giants like Novo Nordisk and Eli Lilly are fighting the battle in the courts, having filed over 130 lawsuits across 40 states, securing dozens of permanent injunctions against pharmacies and telehealth providers.
Conclusion: A Precarious Future
The compounded GLP-1 market is a case study in how rapid technological innovation and extreme consumer demand can outpace the slow, deliberate machinery of federal regulation. While the FDA has made progress in closing the legal loopholes that allowed the "wild west" of weight loss to flourish, the sheer size of the market—and the entrenched financial interests of the players involved—suggest that the struggle for patient safety is far from over.
For now, patients are left to navigate a minefield of conflicting information, predatory subscription models, and potentially dangerous, misbranded medical products. Until the legal status of these "copies" is finalized and the enforcement of safety standards is made uniform, the promise of affordable weight loss remains a dangerous proposition for millions of Americans.
About the Author
